Signal Proxy Intelligence Recommends AGAINST Moleculin Biotech, Inc. Executive Compensation Ahead of Oct. 9, 2026 Annual Meeting (NASDAQ:MBRX)
Independent research firm publishes item-by-item recommendations on all seven ballot measures within 2 days of the
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
SIGNAL
PROXY INTELLIGENCE
New York, NY – 2026-08-26 · Ticker: NASDAQ:MBRX
Signal Proxy Intelligence Recommends AGAINST Moleculin Biotech, Inc. Executive Compensation Ahead of Oct. 9, 2026 Annual Meeting
Independent research firm publishes item-by-item recommendations on all seven ballot measures within 2 days of the company’s proxy filing. (Exceeds SPI’s standing 48-hour / T+2 commitment; the time stated above is the actual elapsed time to publication.)
NEW YORK, NY — Signal Proxy Intelligence, the independent proxy research division of Signal Law Group, today published its recommendations for the Oct. 9, 2026 annual meeting of Moleculin Biotech, Inc. (NASDAQ:MBRX). SPI issued a recommendation on each of the seven items on the ballot, published 2 days after the company’s definitive proxy statement was accepted on EDGAR.
Reviewing the ballot from the perspective of the common shareholder and using publicly available information only, SPI assigned the meeting a concern band of Elevated. The firm recommends AGAINST on the advisory vote on executive compensation, citing that 2025 say-on-pay support was approximately 63%, below the Company’s expectations.
On the election of directors, SPI recommends FOR the director nominees as presented on the ballot.
“This ballot included one item where our recommendation diverged from the board’s under our published framework. The meeting carries a concern band of Elevated, and the full rationale for each recommendation is documented in the report.”
— Hayden Smith, Head of Proxy Research
SPI recommends AGAINST on the following item:
- AGAINST on Item 4 (To vote on a non-binding, advisory resolution to approve executive compensation.): 2025 say-on-pay support was approximately 63%, below the Company’s expectations.
SPI will publish a separate post-meeting divergence report comparing its recommendations to those of the incumbent proxy advisors after the meeting results are available.
The complete item-by-item analysis, including the rationale for each recommendation, is available at https://www.signallawgroup.com/proxies/moleculin-biotech-inc-2026-10-09/.
Ballot Summary: Recommendation by Item
| Item | Title | SPI Recommendation |
|---|---|---|
| 1 | To elect five Board nominees to the Board of Directors of the Company, each to serve until the 2027 annual meeting of stockholders of the Company or until such person’s successor is qualified and elected. | FOR |
| 2 | To ratify the appointment of Grant Thornton, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. | FOR |
| 3 | To approve an amendment to the Moleculin Biotech, Inc. 2024 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder. | FOR |
| 4 | To vote on a non-binding, advisory resolution to approve executive compensation. | AGAINST |
| 5 | To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to eliminate supermajority voting requirements to amend the Amended and Restated Certificate of Incorporation. | FOR |
| 6 | To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to grant our Board of Directors authority to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a reverse stock split ratio of between 1-for-2 to 1-for-20 (or any whole number in between), as determined by the Board in its sole discretion, prior to the one-year anniversary of this Annual Meeting. | FOR |
| 7 | To authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the above proposals. | FOR |
About Signal Proxy Intelligence
SPI is the independent proxy research division of Signal Law Group, an independent research and investigations firm. SPI publishes FOR / AGAINST / WITHHOLD recommendations on every item of every covered proxy ballot within 48 hours of filing, analyzing each measure from the perspective of the common shareholder using publicly available information. SPI accepts no revenue from the companies it covers. Every SPI recommendation is timestamped at publication, fingerprinted, and reconciled against the company’s reported vote.
Media contact
Rochelle Welner
contact@signallawgroup.com
# # #
SPI is an operating company of Signal Law Group, an independent research and investigations firm. SPI is not a law firm, does not provide legal advice, and is not an investment adviser. The recommendations and analysis in this release are independent research provided for informational purposes only. They do not constitute voting advice, investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. Recipients should conduct their own independent analysis and consult their own advisors before making any voting or investment decision. SPI accepts no revenue from the companies it covers.
